14:43 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies identified a pyrimidinone-based inhibitor of TLR4 that could help treat MI. Chemical synthesis and screening of peptidomimetic analogs of a previously identified TLR4 inhibitor peptide in...
20:32 , May 23, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting TLR4 signaling could help treat cerebral cavernous malformation (CCM). In 188 patients with familial CCM, two SNPs on TLR4 (rs10759930 and rs10759931) were associated with high...
22:26 , May 18, 2017 |  BC Innovations  |  Targets & Mechanisms

Degrading NASH

Inflammation is one of the primary drivers of non-alcoholic steatohepatitis (NASH), but decreasing inflammation without creating susceptibility to infection remains a challenge for the field. In Nature Medicine this month, a Chinese team described how...
15:56 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest the cucurbitane analog mogroside IIIE and other TLR4 inhibitors could help treat pulmonary fibrosis. In primary lung fibroblasts from a mouse model of the disease, mogroside IIIE decreased fibroblast...
07:00 , May 12, 2016 |  BC Innovations  |  Targets & Mechanisms

Another shot at the flu

While most efforts to suppress flu focus on boosting the immune system through vaccination, a group at Yale University has found evidence showing it is the inflammatory response to infection, not the infection itself, that...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Scleroderma Toll-like receptor 4 (TLR4); fibronectin extra domain A (FnEDA) In vitro and mouse studies suggest inhibiting TLR4 signaling in skin lesions could help...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cardiovascular disease; sickle cell disease (SCD) Hemopexin (HPX); toll-like receptor 4 (TLR4) Mouse studies suggest TLR4 blockade or recombinant HPX could help prevent SCD-associated acute...
07:00 , Sep 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Toll-like receptor 4 (TLR4); fibrinogen In vitro and mouse studies suggest blocking the interaction between fibrinogen cleavage products and TLR4...
07:00 , May 16, 2013 |  BC Innovations  |  Cover Story

Eritoran insight for influenza treatment

A University of Maryland School of Medicine team has used a toll-like receptor 4 antagonist to treat influenza in mice. 1 The results provide a repurposing opportunity for Eisai Co. Ltd. 's toll-like receptor 4...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Toll-like receptor 4 (TLR4) Rodent studies suggest a lipid A analog that blocks TLR4 activation could help treat...